WAG Related Earnings News
-
Walgreen (WAG) / Alliance Boots Synergies Tracking In-Line
-
AmerisourceBergen (ABC) Likely to Score Another Win Against McKesson (MCK)
-
AmerisourceBergen (ABC) Not Fully Reflecting Walgreens Deal - Goldman Sachs
-
Express Scripts (ESRX) Pricing Aggressively, Leerink Swann Maintains Buy
-
Cardinal Health (CAH) Needs CVS Renewal After Walgreen Loss - Analyst
-
Goldman Sachs Downgrades Walgreen (WAG) to Buy, Less Upside Potential
-
JPMorgan Upgrades Walgreen (WAG) to Overweight
-
Cardinal Health (CAH), Walgreen (WAG) Pharma Distribution Contract Won't be Renewed
-
UPDATE: Walgreen Company (WAG) Tops Q2 EPS by 2c; Front-End Comps Down 2.6%
-
UPDATE: Walgreen (WAG) Ramps on UBS Upgrade; Invest for 'Big Picture'
-
Goldman Sachs Downgrades CVS Caremark (CVS) to Neutral, Few Catalysts
-
Walgreens (WAG), Alliance Boots Aim for Aggregate Sales of $130B by FY16
-
Jefferies Upgrades Walgreen (WAG) to Buy
-
Goldman Sachs Lifts PT on Walgreen (WAG), Maintains Top Rating Post Q1 Noise
-
Christmas Comes Early For For Walgreen (WAG) Bulls
-
Walgreen (WAG) Misses Q1 Expectations on Costs; Still Feels Express Scripts Impact
-
Walgreen Company (WAG) Misses Q1 EPS by 12c
-
CVS (CVS) Taking Walgreen (WAG) Share - Analyst
-
Walgreen (WAG) Shares Sink as Q4 Sales Decline YoY
-
Walgreen Company (WAG) Tops Q4 EPS by 7c
-
Jefferies Maintains a 'Hold' on Walgreen (WAG); Key Takeaways From NYC Meeting w/ Mgmt
-
CVS (CVS) Comments on Walgreens/Express Scripts Deal; Raises Estimate of Impact by 5c/Share
-
Goldman Sachs Maintains a 'Neutral' on Rite-Aid (RAD); Same-Store Sales Reflect Impact of Generics
-
Walgreen Company (WAG) Reports In-Line Q3 EPS; Boosts Dividend
-
UBS Reiterates a 'Neutral' on Rite-Aid (RAD); A Few Longer-Term Tailwinds, But Staying Sidelined For Now
-
UBS Maintains a 'Buy' on Cardinal Health (CAH); Color on Safeway Contract
-
UBS Raises Numbers on CVS Caremark (CVS); Comments From Conference Call
-
UBS Maintains a 'Buy' on Walgreen (WAG); Downside Risk Priced In, Creating Favorable Risk/Reward Balance
-
Walgreen (WAG) Tops Q2 Views Amid Light Flu Season; PSC Takes Off in Sign-Ups
-
Walgreen Company (WAG) Tops Q2 EPS by 1c
-
Jefferies Maintains a 'Buy' on CVS Caremark (CVS); A Superior Model
-
UBS Maintains a 'Buy' on CVS Caremark (CVS); Raising FY12/13 EPS Estimates
-
Walgreen (WAG) Shares Hit After Q1 Miss
-
Walgreen Company (WAG) Misses Q1 EPS by 4c; Comps Up 2.5%
-
Highlights From WAG's Q4 Conference Call: Substantial Progress on Our Transformation Strategy
-
Walgreen (WAG) Slumps Amid Q4 Beat: CFO Says No Express Scripts (ESRX) Contract Will Be Negative to Earnings
-
Walgreen (WAG) Shares Falling as Exec on Call Says Plans 'Not to be Part' of Express Scripts (ESRX) Network
-
Walgreen (WAG) Tops Q4 Views; No Express Scripts Resolution Yet
-
Walgreen (WAG) Tops Q4 EPS by 2c; Comps Up 4.4%; Authorizes $2B Buyback
-
Q4 Preview: Walgreen (WAG) Investors Looking for Express Scripts, Generic Drug Updates
-
Q2 Preview: CVS (CVS) Looking to PBM to Continue Strong Results
-
Highlights From Walgreens (WAG) Q3 Conference Call, Solid Quarter Leaves Company on Tract
-
Walgreen (WAG) Beats Q3 Views, Express Scripts (ESRX) Decision Weighs
-
Walgreen Company (WAG) Posts Q3 EPS of 65c, Beats by 3c; Comps Up 4.1%
-
Q1 Preview: CVS (CVS) May Have Prescription for Beat on Aetna Contract
-
Highlights From WAG's Q2 Conference Call: Record Sales and Earnings Contributed to Third Consecutive Qtr of Double Digit EPS Growth
-
Walgreen (WAG) Q2 Profit Jumps 10%; Results In Line
-
Walgreen Co. (WAG) Reports In-Line Q2 EPS of 80c, Comps Up 4.1%
-
Walgreen (WAG) Trades Strong as Q1 Numbers are Just What the Doctor Ordered
-
Walgreens (WAG) Reports Q1 EPS of 62c, Beats by 9c; Comps Up 0.8%
Back to WAG Stock Lookup
